One event. Multiple sources.
Health

Ivonescimab significantly improves overall survival versus pembrolizumab in advanced lung cancer

1 publisher first detected 2% of 49 Health publishers

Headline as filed by Medical Xpress.

Compare coverage — 1 report

Every publisher that filed on this event, earliest first, with each one's headline, summary, times and how long after the first report they filed.
Publisher Headline Summary Published Detected Delay Source Status
Medical Xpress Ivonescimab significantly improves overall survival versus pembrolizumab in advanced lung cancer
Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a pr
0m medicalxpress.com First

Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.

Reader comments

Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.

Nobody has commented on this story yet.

Add a comment

Up to 2,000 characters. Links are not accepted. Blank lines separate paragraphs.

In this story
NSCLC 5 PD-L 2

Related coverage

connected by shared subjects